rhTPO、rhIL-11联合生血宝合剂治疗ALL患者CIT疗效研究  

Study on the Efficacy of rhTPO,rhIL-11 Combined with Shengxuebao Mixture in the Treatment of CIT in ALL Patients

作　　者：王秋红[1] 郑冬丽[1] 司艳娟 WANG Qiu-hong;ZHENG Dong-li;SI Yan-juan(Department of Gastroenterology and Hematology,Jiyuan People's Hospital,Jiyuan 454000,China)

机构地区：[1]济源市人民医院消化血液科,济源454000

出　　处：《中国合理用药探索》2021年第11期62-66,共5页Chinese Journal of Rational Drug Use

基　　金：河南省医学科技攻关计划项目(2018020820)。

摘　　要：目的:探讨重组人血小板生成素(rhTPO)、重组人白介素-11(rhIL-11)联合生血宝合剂治疗急性淋巴细胞白血病(ALL)患者化疗所致血小板减少症(CIT)疗效。方法:选取2018年6月~2020年6月本院收治的成人ALL患者中因长春地辛、柔红霉素、左旋门冬酰胺酶和地塞米松(VDLD)方案化疗所致CIT者98例作为研究对象,根据治疗方案分为A组(n=41)和B组(n=57)。A组采用rhTPO+rhIL-11+生血宝合剂治疗,B组采用rhIL-11+生血宝合剂治疗,两组疗程14天或至血小板计数>100×10^(9)/L。比较两组治疗有效率、血小板计数下降的最低值、血小板计数恢复最高值、血小板计数开始上升时间、血小板计数达到峰值时间、血小板计数<70×10^(9)/L持续时间、血小板计数恢复至100×10^(9)/L时间、血小板输注次数、不良反应发生率。结果:A组治疗有效率、血小板计数下降的最低值、血小板计数恢复最高值均高于B组,血小板计数开始上升时间、血小板计数达到峰值时间、血小板计数<70×10^(9)/L持续时间、血小板计数恢复至100×10^(9)/L时间均短于B组,血小板输注次数少于B组(P<0.05),两组不良反应发生率比较无统计学差异(P>0.05)。结论:rhTPO、rhIL-11、生血宝合剂联合治疗ALL患者CIT起效快速,疗效更好,且安全可靠。Objective:To investigate the therapeutic effect of recombinant human thrombopoietin(rhTPO),recombinant human interleukin-11(rhIL-11)and Shengxuebao mixture in the treatment of acute lymphoblastic leukemia(ALL)chemotherapy-induced thrombocytopenia(CIT).Methods:A total of 98 cases of adult ALL patients from June 2018 to June 2020 with CIT caused by chemotherapy of the vindesine,daunorubicin,L-asparaginase and dexamethasone(VDLD)regimen were selected as the research subjects.According to the treatment method,the patients were divided into group A(n=41)and group B(n=57).Group A was treated with rhTPO+rhIL-11+Shengxuebao mixture,group B was treated with rhIL-11+Shengxuebao mixture,and both groups were treated for 14 days or until the platelet count was greater than 100×10^(9)/L.The efficacy rate,the lowest value of platelet count decline,the highest value of platelet count recovery,the time when the platelet count starts to rise,the time when the platelet count reaches the peak,the duration of platelet count below 70×10^(9)/L,time for the platelet count recover to 100×10^(9)/L,the number of platelet transfusions,and the rate of adverse reactions between the two groups were compared.Results:The effective rate of treatment,the lowest value of platelet count decline,and the highest value of platelet count recovery in group A were higher than those in group B.The time when platelet count began to rise,the time when platelet count reached peak value,the duration of platelet count lower than 70×10^(9)/L,and the time to recover the platelet count to 100×10^(9)/L in group A were shorter than those of group B.And the number of platelet transfusions in group A was less than that of group B(P<0.05).There was no significant difference in the rate of adverse reactions between the two groups(P>0.05).Conclusion:The combination of rhTPO,rhIL-11,and Shengxuebao mixture in the treatment of ALL patients with CIT has a rapid onset and good effect,which is safe and reliable.

关 键 词：重组人血小板生成素 重组人白介素-11 生血宝合剂 急性淋巴细胞白血病 化疗所致血小板减少症 

分 类 号：R969[医药卫生—药理学]